4-10 Week Observational Study Comparing 3 Management Strategies for Obstructive Chronic BronchoPneumopathy (OCBP) in Common Clinical Practice (OBALPA)

Civil Hospices of Lyon logo

Civil Hospices of Lyon

Status

Unknown

Conditions

Obstructive Chronic BronchoPneumopathy (OCBP)

Study type

Observational

Funder types

Other
Industry

Identifiers

NCT01885247
2012-746

Details and patient eligibility

About

The management of patients with Obstructive Chronic BronchoPneumopathy (OCBP) is based on a progression of therapeutic options and on a sensitization to physical activity. For these patients selected on OCBP stage 2, the treatment options include Long Acting Beta-Agonist Bronchodilator (LABA) or Long Acting Muscarinic Antagonist Anticholinergic (LAMA) or both (LAMA+LABA). The purpose of this study is to observe in common clinical practice the benefit of physical activity on quality of life, dyspnoea and walking distance for these patients under treatment (LABA and/or LAMA) and to determine whether these 3 medical strategies (LABA/LAMA/LABA+LAMA) benefit from physical activity.

Enrollment

100 estimated patients

Sex

All

Ages

40 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients with Obstructive Chronic BronchoPneumopathy stage ≥ 2.
  • Patients under treatment with LABA or LAMA or LABA+LAMA since at least 1 month.
  • VEMS/CVF<70%
  • VEMS<80%
  • Patients without regular physical activity and without physical activity program since 1 year.

Exclusion criteria

  • Patients under treatment with LABA + inhaled Corticoids.
  • Contraindication to physical activity.
  • Patients with previous history of respiratory exacerbations.

Trial contacts and locations

1

Loading...

Central trial contact

Gilles DEVOUASSOUX, MD, PhD; Isabelle DELFOUR

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems